Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023
February 07, 2023 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD
February 02, 2023 09:00 ET
|
Frontera Therapeutics
BEDFORD, Mass. and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
February 02, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went...
Age-Related Macular Degeneration Market Size Worth USD 14.98 Billion by 2030 at 8.1% CAGR – Report by Market Research Future (MRFR)
November 14, 2022 09:53 ET
|
Market Research Future
New York, USA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Age-Related Macular Degeneration Market Overview: According to a Comprehensive Research Report by Market Research Future (MRFR), “Age-Related...
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022
November 10, 2022 16:59 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on...
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
November 09, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...
Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight
September 19, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight DelveInsight’s Wet AMD pipeline analysis depicts a robust...
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
August 22, 2022 01:05 ET
|
Kinarus Therapeutic Holding AG
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2...
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
August 22, 2022 01:00 ET
|
Kinarus Therapeutic Holding AG
Financing to be drawn in tranchesFinancing will enable Kinarus to advance the clinical development of KIN001 Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS)...
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
August 11, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today...